Sex: U
Vaccine: COVID19
Symptoms: Nausea, Pyrexia, Vaccination site erythema, Vaccination site pain, Vomiting
Clinical narrative: Moderate malaise/feeling sick present with some interference with activity; Mild fatigue and no interference with activity; Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch); Mild injection site redness; Mild fever (100.4 to 101.2 °F); Mild muscle pain and no interference with activity; Joint pain and no interference with activity; Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting; Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting; This spontaneous case was reported by a non-health professional and describes the occurrence of MALAISE (Moderate malaise/feeling sick present with some interference with activity), FATIGUE (Mild fatigue and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness) and PYREXIA (Mild fever (100.4 to 101.2 °F)) in a patient of an unknown age and gender who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    In December 2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (unknown route) 1 dosage form. In December 2023, the patient experienced MALAISE (Moderate malaise/feeling sick present with some interference with activity), FATIGUE (Mild fatigue and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), PYREXIA (Mild fever (100.4 to 101.2 °F)), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity), NAUSEA (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting) and VOMITING (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting). At the time of the report, MALAISE (Moderate malaise/feeling sick present with some interference with activity), FATIGUE (Mild fatigue and no interference with activity), VACCINATION SITE PAIN (Mild injection site pain and no interference with activity/Mild injection site tenderness (tender to touch)), VACCINATION SITE ERYTHEMA (Mild injection site redness), PYREXIA (Mild fever (100.4 to 101.2 °F)), MYALGIA (Mild muscle pain and no interference with activity), ARTHRALGIA (Joint pain and no interference with activity), NAUSEA (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting) and VOMITING (Moderate nausea/vomiting and some interference with activity or greater than 2 episodes of nausea/vomiting) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In December 2023, Body temperature: Mild fever (100.4 to 101.2 °F).         Subject ID was reported and Subject ID was reported.  Concomitant medication not reported.   It was reported that the patient experienced the events anytime during the 2 days after the COVID-19 vaccination, which occurred Monday, Dec 18, 2023 and Tuesday, Dec 19, 2023.  Treatment medication not reported.   This case was linked to US-MODERNATX, INC.-MOD-2024-756041 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2024-756041:Same reporter